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Donor organ shortage, growing waiting lists and substantial organ discard rates are
key problems in transplantation. The critical importance of organ quality in determining
long-term function is becoming increasingly clear. However, organ quality is difficult to
predict. The lack of good measures of organ quality is a serious challenge in terms
of acceptance and allocation of an organ. The underlying review summarizes currently
available methods used to assess donor organ quality such as histopathology, clinical
scores and machine perfusion characteristics with special focus on molecular analyses
of kidney quality. The majority of studies testing molecular markers of organ quality
focused on identifying organs at risk for delayed graft function, yet without prediction
of long-term graft outcome. Recently, interest has emerged in looking for molecular
markers associated with biological age to predict organ quality. However, molecular
gene sets have not entered the clinical routine or impacted discard rates so far.
The current review critically discusses the potential reasons why clinically applicable
molecular quality assessment using early kidney biopsies might not have been achieved
yet. Besides a critical analysis of the inherent limitations of surrogate markers used
for organ quality, i.e., delayed graft function, the intrinsic methodological limitations
of studies assessing organ quality will be discussed. These comprise the multitude of
unpredictable hits as well as lack of markers of nephron mass, functional reserve and
regenerative capacity.
Keywords: marginal organs, molecular diagnostics, implant biopsies, organ quality, surrogate marker
Abbreviations: AKI, acute kidney injury; CIT, cold ischemia time; D, donor; DBD, donation after brain death; DCD,
donation after cardiac death; DD, deceased donor; DGF, delayed graft function; ECD, extended criteria donor; EVKP, score
ex vivo kidney perfusion score; GFR, glomerular filtration rate; HCV, hepatitis C; I/RI, ischemia reperfusion injury; IRRATs,
injury and repair response associated transcripts; KDPI, kidney donor percentile index; KDRI, kidney donor risk index;
LD, living donor; MAPI, Maryland aggregate pathology index; PBTs, pathogenesis based transcript sets; PRA, panel reactive
antigen; R, recipient; SCD, standard criteria donor; TPL, transplantation.
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BACKGROUND
Good organ quality is the basis for successful long-term
transplant outcome. The ability to withstand and repair immune
and non-immune mediated injury and the number of nephrons
to match the increased and persistent metabolic demand to a
single kidney characterize optimal kidney organ quality with
the potential to best long-term function. Hence, a robust
assessment of kidney quality at time of transplantation is
needed, in particular in donors with suboptimal conditions,
i.e., marginal donors with old age, uncertain medical history,
long ischemia time or pre-donation renal failure. In case of
doubt clinicians will err on the side of caution and decide
on discarding the organ, despite organ shortage and growing
waiting lists. This is reflected in the high kidney discard rates
in the US despite significant efforts to expand the donor
pool. Nearly 20% of kidneys recovered are discarded, mainly
based on procurement biopsies as method to assess organ
quality (1–4). In Europe, where procurement biopsies are
rarely performed, kidney discard rates are significantly lower
and this is associated with saved patient life years (4, 5).
This difference between US and European allocation practice
underscores the need for more reliable and objective methods
for organ quality assessment, especially in marginal donors, to
decrease the number of discarded organs. So far, no evaluation
process has sufficient discriminatory potential to guide the
clinician and implanting surgeon team whether to accept or
discard an organ. Currently available methods for assessment of
organ quality are summarized in Table 1 and discussed in the
following paragraphs.
CURRENTLY AVAILABLE METHODS FOR
ASSESSMENT OF ORGAN QUALITY
Histopathology
In 1995, the seminal paper on procurement biopsies by Gaber
et al. presented a significantly increased rate of delayed graft
function (DGF) and graft loss with glomerulosclerosis of >20%
(6). However, accumulating data in the last 25 years questions
the utility of procurement biopsies for evaluating donor kidneys
(3, 7, 8). A systematic review by Wang et al. reported that
all 47 published studies on kidney biopsies were retrospective,
poor in design, and the results were heterogeneous. The percent
glomerulosclerosis was most often examined and failed to predict
graft failure in 7 out of 14 studies (7).
Analyzing biopsy findings it is necessary to distinguish
between pre-implantation biopsies, performed immediately
before implantation, and procurement biopsies, taken at time of
donor kidney retrieval (9). Histology, in contrast to molecular
changes, is expected to be similar in pre-implantation and
procurement biopsies. For allocation purposes, focus lies
on the procurement biopsy. As time is an important factor
in the allocation process, these biopsies are evaluated on
frozen sections stained with hematoxylin-eosin and not in
paraffin-embedded tissues stained with periodic-acid-schiff,
masson trichrome, and methenamine silver. Also, evaluation
is done by on-call pathologists often not by an experienced
renal pathologist. Furthermore, no consensus exists regarding
use of wedge biopsies or core needle biopsies. All these
factors pose problems. Hence, classification of histological
lesions might differ when evaluated on frozen vs. paraffin
embedded sections and interpretation might vary between
on-call pathologists vs. experienced nephro pathologists
contributing to the poor quality with missing information,
lack of concordance and reproducibility (8–12). Even the
agreement between expert renal transplant pathologists were
only moderate to poor at Banff Histopathological Consensus
meeting for preimplantation kidney biopsies with most interclass
correlations less than 0.5 (12). In addition, intrinsic differences
between wedge biopsies, that preferentially evaluate the
subcapsular zone overestimating glomerulosclerosis, and core
needle biopsies, that preferentially represent the cortex, further
impact comparisons between various practices of procurement
biopsies (9).
Finally, no consensus exists regarding the grading system
to be used for interpretation of procurement biopsies. Besides
the Banff grading system scoring individual lesions (12),
several composite histological scoring systems have been
described (7, 9). Yet, most histological composite scores lack
validation in independent cohorts as well as testing of their
predictive power in multivariate analyses including donor
age and organ function and hence they might erroneously
appear as independent predictors of graft failure. These facts
underline the difficulty to predict long-term graft outcome
based on histological evaluation of procurement biopsies (13).
All these limitations translate into high discordance between
two biopsies obtained of the same kidney (8) and also
contribute to the high discrepancy in discard rates between
centers (2, 3).
Graft survival rates of unilaterally discarded kidneys might
indeed still be acceptable for some patients (2, 8). One-year
death censored graft survival rate of recipients from unilaterally
discarded kidneys due to donor factors (in particular biopsy
findings) has been reported to be over 90% and five-year death
censored graft survival was >85% (2). This underscores the fact
that the currently available scores for organ assessment using
histology inaccurately capture organ quality and the gain of life
years for the individual patient.
Clinical Scores
The first clinical parameter found to be negatively associated
with graft survival was age (13, 14). Besides age, established
cardiovascular co-morbidities also associate with graft survival
(15). Hence, common variables used in all scoring systems
include donor age, history of hypertension and serum creatinine,
altogether being surrogate markers of reduced nephron mass and
extent of established injury and repair capacity, key donor factors
contributing to long-term graft outcome (13, 16). However, these
clinical markers lack robustness and standardization as organ
quality metrics.
The recently introduced KDRI score (resp. kidney donor
percentile index KDPI) reflects the rate of graft failure relative to a
healthy 40-year old donor. This score was originally based on 14
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TABLE 1 | Comparison of different assessment tools to evaluate organ quality in kidney transplantation.
Method Scores Strength General intrinsic limitations
Organ inspection by
surgeon
Identification of renal tumors
and vascular and anatomical
variations and quality of
perfusion after retrieval
Interobserver variability, unclear predictive value
Kidney biopsy Different scores evaluating






Offers the potential to detect
preexisting lesions associated




Interpretation on frozen sections differ from paraffin
embedded formalin fixed samples. This however is
time consuming (up to 5 hours), hence increasing
cold ischemia time
Sampling error (wedge versus needle biopsy
different results)





Practical for clinical routine
application (easy, quick,
information available at time of
decision making)
Categorical classification underestimating variability
Original model defining ECD did not include
validation cohort
Donor risk scores
Kidney Donor Risk Index (KDRI)
(including 14 variables)
Donor-only KDRI (including 10
donor characteristics) (most
recently introduced)
Assessment of graft quality as a
spectrum
Can easily be calculated based
on donor factors
Does not account for injury during procurement
Does not account for anatomical abnormalities
Does not account for any recipient parameter
(including immunological risks)
Overall c statistic low with 0.62; c statistic for upper
and lower quartile of KDRI 0.78
Falsely elevated in HCV + organs and increased
creatinine due to acute kidney injury
Not intended to be used as discriminatory tool to






Renovascular resistance index Overall c statistic low with 0.58 for prediction of
DGF, association with graft survival unclear
perfusion Biomarkers within perfusate Biomarkers (e.g., NAG, H-FABP, miR21), predictors






EVKP score (macroscopic appearance, blood flow,
urine output), urine biomarkers (Endothelin 1,
NGAL, KIM 1 and others)
donor characteristics (donor age, race, history of hypertension,
history of diabetes, serum creatinine, cerebrovascular cause of
death, height, weight, donation after cardiac death, hepatitis C
virus status, HLA-B and -DR mismatch, cold ischemia time, en-
bloc kidney transplant, dual kidney transplant) (17–19) and later
reduced to 10 variables, as some information may be missing
at time of transplantation. This is a far more granular tool for
physicians to evaluate the offer and assess generic donor quality
and outcome than the previously used dichotomous extended
criteria donor (ECD) vs. non-ECD classification. Yet, despite
introduction of this more detailed risk index, discard rates in the
US remained unchanged at roughly 18–20% (20).
The differences in discard policies and application of the
KDRI scores are highlighted in a recently published analysis
by Aubert et al. (4). The probability of organ discard for
the same KDRI is significantly higher in the United States
compared to France and the interpolation of a similar organ
use strategy in the United States would generate additional
132’445 allograft life-years over a ten-year observation period
with greatest gain of life years through reduced discard of the
organs with highest KDRI. These differences in applying the
KDRI for accepting organ offers also reflect its limited predictive
power. A recent study showed no significant difference in 5-
year death-censored graft survival between DCD KDPI 61–81
and DCD KDPI ≥ 85 when used for donation after cardiac
death (DCD) kidneys (18). In line with the limited discriminative
power regarding graft failure very high KDPI kidneys may reveal
acceptable outcomes (21–24). Another group showed 5-year
graft survival of 91% using kidneys with KDPI score of 97%
as dual transplants, highlighting that besides KDRI, nephron
mass plays a major role with respect to graft survival (14, 25).
A further a critical issue when using KDRI/KDPI is Hepatitis
C virus (HCV) status having the largest contribution to KDPI
(KDRI b coefficient 1/4.24; “Xb” component 1/4.24). However,
HCV + kidneys are mostly young donors and at current era
with available excellent antiviral treatment for HCV, clinical
outcomes are excellent in HCV negative patients receiving
HCV + deceased-donors (26). The other important critical
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component of KDPI is the pre-donation serum creatinine level,
which might be “falsely” high due to acute kidney injury from
acute tubular necrosis. In a multicenter deceased donor study
of 2,430 kidneys transplanted from 1,298 deceased donors 585
(24%) were from donors with AKI. The analysis did not show
any significant difference in graft survival at 4 years by donor AKI
stage (27).
All these articles question the utility of KDRI/KDPI as single
decision tool with respect to kidney discard policies. Even
though KDRI/KDPI has repeatedly been shown to associate
with graft failure, a high KDRI/KDPI is not synonymous with
graft failure and underscores its limited discriminative power as
single decision tool.
Machine Perfusion
Research and applications of machine-based organ preservation
have experienced a significant revival with the goals to
reduce peri-transplant ischemia reperfusion injury, to facilitate
assessment of organ quality and directed organ therapies, and
to decrease the number of marginal organs to be discarded.
First described as early as 1935 by Carrel and Lindbergh (28),
interest in organ perfusion has re-emerged with the landmark
trial published by Moers et al. (29). Machine perfusion for organ
preservation was associated with a reduction of DGF compared
to cold storage and its application has led to reduced discard
rates of organs (30). However, these positive effects on short-
term function did so far not translate into amarked improvement
in long-term outcomes (31, 32). However, more sophisticated
perfusion methods and cell-based therapies are investigated.
Currently hypothermic machine perfusion is the most widely
used technique, in recent years normothermic machine perfusion
is gaining interest (33).
In addition to positively impacting reperfusion injury
and organ preservation, machine perfusion also offers the
opportunity for organ quality assessment based on perfusate
analysis or measurement of perfusion dynamics such as
intravascular renal resistance. The largest randomized controlled
trial prospectively assessing renal intravascular resistive indexes
on hypothermic machine perfusion and its association with graft
outcome by Jochmans et al. showed that renal resistance at the
end of hypothermic machine perfusion is an independent risk
factor for both DGF and 1-year graft failure, yet the predictive
power was low with a c-statistic of only 0.58 (34). Similar findings
are reported by de Vries et al. and Parikh et al., showing only
modest correlation with early graft function (35, 36). Likewise,
perfusate analyses indicated that biomarkers, such as NAG or
H-FABP, are associated with DGF, but again with low predictive
value in differentiating functioning versus non-functioning grafts
(37). Another group described levels of microRNA-21 (miR-21)
to correlate with early graft function, but no data on association
with long-term graft function is available (38). Hence, so far,
neither dynamic machine perfusion characteristics such as renal
resistance nor machine perfusate biomarkers can be used as
stand-alone criteria for organ quality assessment with sufficient
precision (36, 39).
Yet, novel techniques using normothermic perfusion allow
for further assessments of functional parameter in addition to
the above described flow/resistance markers. Hosgood et al.
(40). described an ex vivo kidney perfusion quality assessment
score (EVKP score) based on macroscopic appearance, renal
blood flow and urine output after ex vivo normothermic kidney
perfusion correlating with DGF but not long-term outcome.
The same group correlated urine biomarkers of injury with this
score. They measured a significant correlation between levels
of urinary endothelin-1 and NGAL and perfusate parameters
as well as between the EVKP score and donor creatinine at
organ retrieval, while no correlation was found for KIM-1 (41).
Similar results, reporting a lack of correlation of KIM-1 with
donor AKI, have also been reported by other groups, likely due
to the fact that KIM-1, in contrast to NGAL, is a rather late
marker of kidney injury. However, the predictive power of these
urinary biomarkers, despite being sensitive for structural kidney
damage, is still unclear. Of note, a large multicenter deceased
donor study of 2,430 kidney transplant recipients from 1298
donors did not find an association of the donor urine injury
biomarkers microalbumin, NGAL, KIM-1, IL-18, and L-FABP
with graft failure at a median follow-up of 4 years, questioning
the predictive utility of urinary biomarker measurements during
normothermic ex vivo perfusion (42).
Future evaluations will show whether novel techniques,
such as normothermic machine perfusion, may allow better
assessment of organ quality and function under near-
physiological conditions (43). A key advantage of machine
perfusion might well be the additional time gained for organ
evaluation and the clinical decision to use or not use the organ.
MOLECULAR DIAGNOSTICS USING
KIDNEY IMPLANTATION BIOPSIES
As outlined above, evaluation of organ quality by clinical scores,
histopathology or perfusion characteristics lacks discriminatory
power to guide clinicians to accept or discard an organ, in
particular in the situation of marginal donors.
Over the recent years molecular analysis of biopsy
samples has become a reliable, technically robust, not too
expensive methodology including transcriptome, proteome and
metabolome technologies. The unbiased, quantitative “omics’
approaches have become standard of care in oncology, classifying
tumors and individualizing therapy. Hence, great expectations
have been based on molecular diagnostics as they potentially
offer an alternative, more objective and quantitative method
for organ evaluation. Molecular profiling indeed demonstrated
to go beyond histopathologic evaluation being able to detect
changes not captured by histopathology. In a previous review
we have summarized molecular studies of 0-hour biopsies (both
pre-implantation and post-reperfusion) published till 2010
(44). It could be shown that transcriptome profiles provide
a quantitative measurement of inflammatory burden, detect
coordinated activation of pathways of immune activation,
defense response, oxidative stress and a parallel inhibition
of metabolism and transport or ion binding. In particular,
transcriptome patterns identified changes in kidneys such as
susceptibility to DGF, which was not reflected using clinical
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and histopathological scores (45). However, despite the number
of promising findings, no robust set of predictive molecular
markers for organ quality measurement had been identified in
these early studies.
Since then a number of new studies have been conducted
to further assess the potential to evaluate organ quality and
transplant outcomes. Table 2 summarizes studies on molecular
analyses of peri-transplant biopsies assessing organ quality that
have been published since 2011 and are listed in PubMed.
A majority of studies focused on DGF as a surrogate marker
for organ quality and early outcome (46–52). They largely
confirm the earlier findings that DGF is usually better predicted
with molecular changes than histology or clinical scores at
time of transplantation (46, 49–52). They identified molecular
changes associated with kidney injury (such as NGAL, syn. LCN2,
KIM1, syn. HAVCR1, NTN1) (46, 49) and aging (CDKN2A)
(50–52) as DGF biomarkers. However, these peri-transplant
changes associated with DGF did not allow a robust prediction
of medium- to long-term functional outcomes.
Mas and her group showed that transcript changes associated
with early kidney function but not with DGF per se correlate with
outcome. Kidneys with DGF and also a lowGFR at 1-month post-
transplant showed inferior medium- to long-term outcomes. The
pre-implantation biopsies of these kidneys showed an increased
expression of pathways associated with immune activation and
inflammation. Gene transcripts of CCL5, CXCR4, and ITGB2
discriminated best between low vs. high GFR. This difference in
kidney function remained throughout the period of observation
of 2 years (48, 53). Findings of the Halloran group confirm the
lack of predictive power of gene changes associated with DGF
(54, 55). They identified gene transcript changes associated with
AKI in transplant biopsies. These so-called injury and repair
associated transcripts (IRRATs) correlate with degree of injury,
repair capacity and functional outcome but not with DGF (54,
55). However, with a sufficient long-term follow up of more than
2 years, peri-transplant molecular phenotypes at time of, or early
after transplantation seem not to correlate with medium- to long-
term transplant function. Molecular changes in 6-week protocol
biopsies correlated with atrophy and scarring at 6 months but
not with future functional decline (47), implant biopsies did not
predict late function (54, 55). In contrast, long-term function
correlated with histopathology changes associated with aging or
clinical scores, in particular donor age (53, 55).
Consequently a number of studies focused on molecular
markers for biological age as parameters for organ quality (50–
52). In particular increased expression of CDKN2A associated
with graft function, probably better reflecting the allostatic
load of “wear and tear” of an organ and its resilience to
cope with the peri- and post-transplant stressors (50–52).
However, the clear added value of markers of biological age
like CDKN2A or others like telomere length, microRNAs or
epigenetic changes to the simple measurement of chronological
age is not clear. In addition, the age allocation bias, i.e., old
kidneys are predominantly given to old recipients, and hence
likely poorer quality organs are transplanted into recipients with
more comorbidities and inferior outcomes, makes it difficult to
identify and validate robust quality markers in old kidneys (55).
An interesting, recent study analyzed gene expression in cell
infiltrates at time of transplantation and 4months post-transplant
(56). This study indicated gene expression of inflammatory
and fibrotic markers at 4 months, and differences between
4 months and baseline, correlated negatively with renal function
up to 5 years. Another small, exploratory but cutting-edge
methodology study by Kaisar et al. (57). suggests that proteomics
analyses are able to discriminate different outcomes that were
not predicted by common evaluation methods such as clinical
(KDPI), histology or AKI scores (57). These promising studies
need further validation and larger numbers.
In general none of the molecular analyses outlined here have
entered the clinical routine diagnostics and organ quality is still
evaluated exclusively by clinical and histopathology-based scores.
The question is why these molecular analyses have not
yet identified robust quality markers and hence successfully
translated into clinical useful tests? This might be due to
intrinsic limitations of molecular studies, selection of insufficient
surrogate markers and end points for outcome studies, or the
principal unpredictability of long-term outcomes with donor
organ characteristics given heterogeneity and multitude of hits
during the post-transplant life of the donor kidney.
Molecular analyses of donor kidney biopsies might not depict
structural changes or reflect nephron mass. They measure tissue
cell mixtures depending on the location of the biopsy site, cannot
predict the multitude of additional immune and non-immune
hits and recipient factors that occur in the long run. They are
drowned by the tidal wave in expression changes due to brain
death and the associated SIRS-like syndrome.
The surrogate markers for kidney quality used for the
identification of molecular changes is another likely reason for
the lack of established kidney quality profiles. Delayed graft
function, chronological rather than biological age, incomplete
disease phenotyping, weak markers of kidney function (such as
creatinine), short follow-up periods, small samples sizes or lack
of validation studies all contribute to the still unfulfilled promise
of molecular diagnostics for organ quality assessment.
ORGAN QUALITY ASSESSMENT OF
NON-KIDNEY TRANSPLANTS
Pre-transplantation assessments of organ quality in non-kidney
solid organs primarily rely on clinical scores and markers
assessed during ex vivo machine perfusion. Comparable to
kidney transplantation there is no established molecular
assessment of biopsy samples and few examples are given
below. In-depth analysis of organ quality assessment
measures for other organs than the kidney is out of the
scope of this review.
In liver transplantation, organ quality has been correlated
with cumulative bile acid production and coagulation parameters
(58). Also metabolomic signatures associated with early
graft function comprising key pathways involved in lipid
homeostasis and histidine pathway have been described (59).
With respect to analysis of molecular markers, investigation
of microRNA profiles in graft preservation solutions has been





































Follow up Test and outcome markers Findings Strengths and limitations with
focus on quality assessment
DGF as surrogate for organ quality and early outcome
(46) Implantation1 34 DD + 9
controls (tumor-
nephrectomies)
Early post-TPL 4 candidate AKI genes studied
in micro-dissected
tubulointerstitial vs. glomerular
segments: KIM1 (i.e., HAVCR1),




• Upregulation of NGAL and KIM1 in DGF
• In multivariate model only D age significantly
associated with DGF
Strengths:
• Analysis of micro-dissected
samples
Limitations:
• No validation set
• Low numbers




14 LD + 93 DD
Indication
biopsies
≥ 2 years Pathogenesis based transcript




• The molecular phenotype correlates with
previous DGF
• No difference in PBTs between LD and DD
• Molecular phenotype correlates with 6 month
atrophy and scarring
• Molecular phenotype did not predict future
functional decline or allograft loss
Strengths:
• long-term analysis incl.
assessment of graft loss
Limitations:
• no validation set








≥ 1 year Microarrays (validation in
independent sample set)
Tested outcome:
DGF and 1 month GFR
(≤ / > 45 ml/min/
1.73 m2)
• Clinical variables pre-transplant did not
identify kidneys with better or poorer function
during first year
• 1 month function predictive of 1 year function
• Low vs. high GFR within DGF group differ in
inflammation and immune activation transcripts
pre-TPL, at month 1 and throughout first year
• DGF not associated with 3 month and 1 year
function




• Unbiased gene selection
approach
• GFR at 1 month and 1 year as
outcome marker and not only DGF
Limitations:
• no analysis of longer-term graft















(≤ / > 45 ml/min/1.73 m2)
• Groups with high vs. low 1 month GFR stay
different at 24 months post-TPL
• D age only clinical marker different in high vs.
low 1 month GFR groups, not race, gender,
CIT, PRA and cause of death
• CCL5, CXCR4 and ITGB2 expression in
pre-implantation biopsies discriminate GFR
high vs. low group at 1 month
Strengths:
• validation set [overlap with (50)]
• Unbiased gene expression
approach
• GFR up to 24 months as
outcome marker
Limitations:
• no analysis of longer-term graft


















































































Follow up Test and outcome markers Findings Strengths and limitations with






3.9 years Unbiased microarray gene
expression approach (validation
set of 27 kidneys)
11 protocol biopsies
Tested outcome: GFR, graft
loss, dialysis
• No difference in kidney outcome with or
without AKI
• Histology did not correlate with DGF, GFR,
recovery of function or IRRAT score
• 30 injury repair response transcripts (IRRATs)
in AKI correlate with function, future recovery,
need for dialysis but not future graft loss
• IRRAT transcripts differ to DGF transcripts
Strengths:
• validation set
• Unbiased gene expression
approach
• Analysis of AKI in allografts




• No peri-TPL biopsies




4.2 years AKI associated. transcripts
(IRRATs), see Famulski et al.
(54)
Tested outcome:
early and 1 and 3 year GFR,
histology, clinical scores, graft
loss
• D and R age, not histology correlate with early
dysfunction
• CAVE: age bias, old kidneys are often
allocated to old Rs
• D age predicts late function
• D age, D age-dependent models such as
KDRI and Irish and histology correlate weakly
with late function
• IRRATs predict early but not late function in
SCD
Strengths:
• independently validated gene set
• Analysis of clinical, morphological
and molecular markers as
predictors of early and late function
Limitations:
• no validation set











1 year 92 pre-selected genes
associated with I/RI injury
Tested outcome:
DGF
Gene expression heterogeneity increases from
procurement to pre-implantation to implantation
biopsies suggesting different organ vulnerability
• Cold storage not associated with significant
transcript changes
• Reperfusion associated with activation of
innate and adaptive immune response and
apoptosis
• Low netrin-1 (NTN1) and higher tubular
atrophy on histology predictive of DGF
Strengths:
• investigation of sequential
biopsies from the same graft
Limitations:
• no validation set
• No long-term follow-up
Molecular markers for biological age as markers for organ quality
(50) Pre-
implantation
120 DD 1 year Comparison of predictive




6 and 12 month function, DGF
• CDKN2A, stronger than telomere length,
predict DGF and 6 and 12 month graft function
• Pre-TPL D risk classification based on
CDKN2A and ECD criteria possible
Strengths:
• assessment of markers of
biological age (yet additive value to
chronological not clear)
Limitations:
• no validation cohort
• Short follow-up



















































































Follow up Test and outcome markers Findings Strengths and limitations with
focus on quality assessment
(51) Pre-
implantation




t1/2 creatinine fall, DGF, 3, 6
and 12 month function
• A score using senescence associated
miRNAs (hsa-miR-217, hsa-miR-125b;
regulators of CDKN2A) combined with D age
and organ type predicts occurrence of DGF
(Sens > 90%, Spec > 60%)
• CDKN2A expression and hsa-miR-217
correlate positively with 12 month function
Strengths:
• Investigation of markers of
biological age
• Concept of allostatic load
Limitations:
• Questionable clear added value of
miRNAs and CDKN2A to
chronological age alone












DGF, creatinine fall 1st week, 3,
6 and 12 month function
• Transcriptional response to reperfusion injury
similar for allografts irrespective of post-TPL
outcome, but magnitude is greater for those
exhibiting DGF
• DGF specific transcripts reveal differential
promotor methylation status
• Pre-implantation TP53, CDKN1A/p21,
CDKN1B/p27 (“BioAge”) associated with 3 and
6 month function
• Molecular signature for allostatic load (burden
of “wear and tear”) reflects age-related
physiological capability and resilience
• DGF is a manifestation of its allostatic load
Strengths:
• Unbiased analysis investigating
genome, transcriptome and
epigenetics
• Concept of allostatic load
Limitations:
• No validation set
• Questionable clear added value of
biological age markers to
chronological age alone
• Short term follow-up
• No assessment of long-term graft
function or loss






DD and 34 LD)
≤5 years Pre-selected genes,
macrophage infiltration
Tested outcome:
graft survival, 4, 24 and 60
month function
• Baseline expression of selected genes did not
correlate with GFR at any time point
• Higher pre-implantation levels of inflammation,
monocyte recruitment, and M1/M2
macrophage transcripts in DD compared to LD
• 4 month fibrosis transcript levels correlate
with long-term function in DD
• Expression of inflammation and fibrosis
markers at 4 months and difference between
4 months and baseline correlate negatively with
medium- and long-term renal function in DD
• TGFb1 best predictor of long-term renal
function in DD
Strengths:
• Broad gene set
• Analysis of graft survival and
outcome up to 5 years
Limitations:
• No validation set
• LD vs. DD impacted by multitude
of factors (D/R age, CIT, dialysis































































































































































































































































































































































































































































































































































































































































































































shown to be predictive of ischemic-type biliary lesions after
liver transplantation, which are the second most common
cause of graft failure after liver transplantation (60). The
ratio of hepatocyte to cholangiocyte-derived miRNAs (with
special focus of miR 122 and miR 222) was predictive of graft
viability (60–62). In pancreas transplantation, assessment
of organ quality is performed during machine perfusion
measuring insulin secretion, acid-base balance and perfusion
characteristics (63). Likewise, in lung transplantation organ
quality assessment is reported through ventilation parameters,
analysis of arterial blood gases on perfusate samples with recent
focus on metabolic components of glucose consumption and
lactate production (64). Other groups indicated that levels of
inflammatory cytokines (65, 66), endothelin-1 (67), adhesion
molecules (68) or neutrophil extracellular traps (69) in lung
perfusate are associated with post-transplant primary graft
function. Similarly, assessment of donor heart quality prior
to transplantation is attempted by analyzing perfusate during
machine perfusion (70).
CRITICAL DISCUSSION OF SURROGATE
MARKERS USED FOR KIDNEY QUALITY
ASSESSMENT
The majority of published studies on molecular assessment of
organ quality used DGF, i.e., transient renal failure immediately
post-transplantation, as surrogate marker for graft quality and
outcome. This is based on the association of reduced graft
survival of DGF kidneys in standard brain death donors (DBD)
shown in some, but not in all studies. The limitations of DGF as a
surrogate outcomemarker for poorer organ quality is highlighted
by the excellent quality and long-term outcomes of DCD organs.
Despite the high percentage of DGF cases these positively
selected cases with usually young age and lack of comorbidities
show good long-term outcomes. Similar lack of correlation with
longer-term outcomes and DGF is seen analyzing mate kidneys.
Donor characteristics rather than ischemia times or DGF rates
determine the long-term performance (71–74).
Moreover, definition of DGF is not uniform (71). More than
10 different definitions are used and most importantly none
of them was associated with poorer graft survival in DCD
kidneys (71). The limitations of DGF as a quality marker is
further underlined as so far no treatment of DGF translated into
significant improvement in long-term outcome (75).
Patho-physiologically the higher risk of DGF in DCD donors
compared to DBD donors can be explained by the unavoidable
extended warm ischemia time and associated increased ischemia-
reperfusion injury. However, full recovery and excellent long-
term graft outcome underline repair capacity and nephron mass
as organ quality determinants.
Hence, not DGF per se but rather ability to recover from DGF
as indicated, e.g., by GFR at 1 month might be a more reliable
marker of long-term graft outcome and quality, as recently
reported by Lee et al. (76). Donor age, donor final creatinine
and cold ischemia time were significantly associated with DGF
recovery status (76). DGF is a syndrome and duration of DGF and
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degree of acute kidney injury is associated with renal outcome,
in transplant and non-transplant settings (77, 78). Extent of
recovery presumably reflects the intrinsic repair capacity of the
donor organ. Age strongly defines repair capacity and this might
explain donor age as the most widely used criterion in all clinical
scores assessing organ quality pre-transplantation (73, 79).
In summary, the post-transplant course is determined by
donor factors, acute peri-transplantation injury as well as
recipient factors. DGF per se is a poor, but most frequently used,
surrogate marker for organ quality (seeTable 2). Hence, the focus
on identifying DGF-associated molecular patterns might be one
reason that so far molecular diagnostics of organ quality has not
translated into clinical decision making. In addition, molecular
assessment of repair capacity and biological tissue aging is still ill
defined. Ongoing work on robust molecular markers of biological
age is promising (seeTable 2) but again has not yet translated into
clinical utility.
Successful organ transplantation is largely defined by a
good and long-term functioning kidney graft. This requires
a sufficient nephron mass to meet the increased, long-term
metabolic demand and stresses of a single kidney in a transplant
recipient. In the unstable setting of brain death and organ
donation donor serum creatinine or estimated GFR are unreliable
markers of nephron mass or reserve capacity. The same applies
to histopathology and clinical scores. The identification of
molecular markers for nephron mass in addition to repair
capacity would be most valuable but yet, has not been achieved.
This might be due in part to the lack of long-term studies. As
shown in Table 2most studies focus on short-term function. The
identification of molecular changes in peri-transplant biopsies
that correlate with long-term function is needed.
PROPOSED APPROACHES TO
OPTIMIZE MOLECULAR DIAGNOSTICS
FOR CLINICAL ROUTINE APPLICATION
Assessment of Nephron Mass by
Molecular Methods: Paired Kidney
Transplantation Study
• Comparison of molecular profiles at implantation biopsy
between kidney pairs from the same donor both
with high eGFR at 1 year post transplantation (i.e.,
eGFR > 60 ml/min/1.73 m2) and kidney pairs from the same
donor with both low eGFR at 1 year post transplantation (i.e.,
eGFR < 30 ml/min/1.73 m2). This should primarily reflect
intrinsic donor factors rather than post-transplant hits and
recipient factors. Note: Ratio for taking follow up of 1 year
only: if taking too long follow up (longer than 1 year) recipient
factors might become additionally relevant.
Assessment of Kidney Regeneration
Capacity: Recovery From AKI (i.e., DGF)
• Comparison of molecular profiles at implantation biopsy
between kidney with low delta of expected and observed
creatinine at 1 year post transplantation (e.g., delta 25%;
i.e., kidney with good regeneration capacity) and kidneys
with high delta of expected and observed creatinine at 1
year (delta > 25%; i.e., kidney with impaired regeneration
capacity). Note: make sure taking only kidney with goodmatch
of recipient/donor weight (i.e., R/D weigh ratio of 0.8–1.2
allowed) (80).
Assessment of Effect of Pumping on
Recovery Form AKI in High Risk Patients
(i.e., Patients With Low Regeneration
Capacity)
• Once molecular profiles of kidney with low regeneration
capacity is characterized: comparison of delta expected-
observed creatinine at 1 year in high risk kidneys preserved
with pumping as compared to delta expected-observed
creatinine in high risk kidneys preserved with cold storage.
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